PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period |
| January 22, 2020 | January 2020 Bond Updates |
|
MADRID and DUBLIN, Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive license agreement for... |
| View more at: https://www.prnewswire.com:443/news-releases/pharmamar-and-jazz-pharmaceuticals-announce-the-us-license-agreement-for-lurbinectedin-is-effective-with-the-expiration-of-the-hsr-waiting-period-300990912.html |
| Related News |